About the Study

Rhabdomyosarcoma: A Study of Different Treatments for Very Low-risk Rhabdomyosarcoma (VLR-RMS) And Low-risk Rhabdomyosarcoma (LR-RMS)

This study is for children and young adults: • 21 years old or younger • Who have rhabdomyosarcoma (RMS) This study looks at how well the standard chemotherapy drugs work to treat VLR-RMS whenchildren and young adults with VLR-RMS disease are given less of those drugs. Getting less chemotherapy drugs is experimental because it has not been proven to work. The drugs participants will receive are vincristine and dactinomycin. Both drugs have been approved by the FDA for the treatment of RMS.

Interested in learning more?

Full Study Name: ARST2032 - A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma